The most effective management for Alzheimer’s and Parkinson’s disease is early detection to delay onset.
Utilising GMDx proprietary analytics, initial research has been able to identify patients with Alzheimer’s Disease (AD) and stratify disease progression.
Initial analyses has shown that GMDx can clearly differentiate between healthy patients (controls) and AD patients.
In initiating development of test for the early detection
of diseases associated with Cognitive Impairment (CI) such as Alzheimer’s Disease, our EDGE is that we understand:
The clinical and individual relevance of being able to identify the likely deaminase source of inherited and/or de novo mutations, and the codon-context of their targeting specificity
That Alzheimer’s and Parkinson’s Disease patients have an ‘inflamed brain’ (i.e. many of the signatures we identify are indicative of the body’s Somatic Hypermutation-like innate immune response to inflammation)